Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference - Archive ouverte HAL Access content directly
Journal Articles Kidney International Year : 2017

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

(1) , (2) , (3, 4) , (5) , (6) , (1) , (7, 8) , (9) , (2) , (10) , (11, 12, 13, 14) , (15) , (7, 8)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Abstract

In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues in the management of these 2 diseases were considered by a global panel of experts. Areas addressed included renal pathology, clinical phenotype and assessment, genetic drivers of disease, acquired drivers of disease, and treatment strategies. In order to help guide clinicians who are caring for such patients, recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options. Knowledge gaps were identified and a prioritized research agenda was proposed to resolve outstanding controversial issues.
Fichier principal
Vignette du fichier
1-s2.0-S0085253816306044-main (1).pdf (651.47 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-02155926 , version 1 (14-06-2019)

Identifiers

  • HAL Id : inserm-02155926 , version 1

Cite

Timothy H.J. Goodship, H Terence Cook, Fadi Fakhouri, Fernando Fervenza, Véronique Frémeaux-Bacchi, et al.. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney International, 2017. ⟨inserm-02155926⟩
79 View
112 Download

Share

Gmail Facebook Twitter LinkedIn More